A Phase 1 interventional study of LY900014 and Insulin Lispro in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-01.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 26th largest by enrollment, is one of 5 that started in 2017, is one of 7 in phase 1, and was the 26th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 127 across the 36 interventional studies. Of the 34 that completed or were terminated, 28 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 183rd largest by enrollment of the 232 interventional ones that give a count, is one of 12 that started in 2017, is one of 76 in phase 1, and was the 130th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs are given by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels in comparison with insulin lispro. The study will last about 7 to 12 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
Drug: LY900014
Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
Drug: Insulin Lispro
Administered SC
Also known as: Ultra-Rapid Lispro
Administered SC
Also known as: LY275585, Humalog
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC)
Pharmacokinetics: Insulin Lispro Area Under the Concentration Curve From Time Zero to 10 Hours Post Dose \[AUC(0-10h)\]
Time frame: Day 1: Pre-dose, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 90, 120, 150, 180, 210, 240, 300, 360, 420, 480, 540, and 600 minutes post-dose
Glucodynamics: Total Amount of Glucose Infused (Gtot)
Glucodynamics: Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp
Time frame: Day 1: Every minute starting from the pre-dose and throughout the duration of the clamp until 10 hours post-dose
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Received at least one dose of study drug | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 6 | 7 |
| Completed | 7 | 7 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Personal reasons | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 6 | 7 |
| Completed | 7 | 6 | 7 | 7 | 5 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1: ABFCED | Sequence 2: BCADFE | Sequence 3: CDBEAF | Sequence 4: DECFBA | Sequence 5: EFDACB | Sequence 6: FAEBDC |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 | 5 | 7 |
| Completed | 7 | 6 | 7 | 7 | 5 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Pharmacokinetics: Insulin Lispro Area Under the Concentration Curve From Time Zero to 10 Hours Post Dose \[AUC(0-10h)\]
| picomole * hour per liter(pmol*/L) | 7 U Humalog | 7 U LY900014 | 15 U Humalog | 15 U LY900014 | 30 U Humalog | 30 U LY900014 |
|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) | 649 ± 16 | 656 ± 17 | 1400 ± 19 | 1450 ± 17 | 3050 ± 18 | 3180 ± 20 |
Glucodynamics: Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp
| milligrams per kilogram (mg/kg) | 7 U Humalog | 7 U LY900014 | 15 U Humalog | 15 U LY900014 | 30 U Humalog | 30 U LY900014 |
|---|---|---|---|---|---|---|
| Glucodynamics: Total Amount of Glucose Infused (Gtot) | 1120 ± 53 | 1080 ± 60 | 1970 ± 44 | 1860 ± 45 | 3290 ± 32 | 3030 ± 36 |
Collected over Baseline to study completion (up to 12 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 7 U LY900014 | 0/40 (0%) | 0/40 (0%) | 7/40 (17.5%) |
| 15 U LY900014 | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| 30 U LY900014 | 0/41 (0%) | 0/41 (0%) | 14/41 (34.1%) |
| 7 U Humalog | 0/40 (0%) | 0/40 (0%) | 8/40 (20%) |
| 15 U Humalog | 0/41 (0%) | 0/41 (0%) | 6/41 (14.6%) |
| 30 U Humalog | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Event | 7 U LY900014 | 15 U LY900014 | 30 U LY900014 | 7 U Humalog | 15 U Humalog | 30 U Humalog |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/40 | 4/40 | 6/41 | 8/40 | 3/41 | 3/40 |
| Injection site reactionGeneral disorders | 1/40 | 1/40 | 6/41 | 0/40 | 2/41 | 0/40 |
| NauseaGastrointestinal disorders | 1/40 | 2/40 | 3/41 | 1/40 | 1/41 | 2/40 |
All Participants who received at least one dose of study drug.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 41.9 ± 11.6 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 15 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 40 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 40 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Overall |
|---|---|
| Germany | 42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Feb 2018, 3 months.
Results were first posted in May 2020, 2 years 2 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Lispro